The partner
Secondary Capital is a direct secondary specialist set up by experienced private markets investors. It buys shares from founders, executives and early investors in late stage private companies that are staying private for longer.
The deals
Alto Pharmacy, 2023: a leading US digital pharmacy offering free delivery and easy access to pharmacists, with more than three million prescriptions fulfilled across twelve markets
SmartRecruiters, 2024: a hiring platform used by around 4,000 customers including Bosch, LinkedIn, Skechers and Visa
What we did
On both transactions we introduced co investors from our family office and private network to Secondary Capital, giving them access to growth companies they could not otherwise reach.
Why secondaries
Buying existing shares in a mature private company can offer a shorter path to an exit, a known business and often a price below the last funding round. Early shareholders gain liquidity without forcing a sale of the company.
Past performance is not a guide to future returns.
To hear about future co investments, call James Innes on 020 7850 4760 or email james.innes@chrystalcapital.com.